-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Shareholders in Cardiovascular Systems (NASDAQ:CSII) Have Lost 69%, as Stock Drops 9.0% This Past Week
Shareholders in Cardiovascular Systems (NASDAQ:CSII) Have Lost 69%, as Stock Drops 9.0% This Past Week
Investing in stocks inevitably means buying into some companies that perform poorly. But long term Cardiovascular Systems, Inc. (NASDAQ:CSII) shareholders have had a particularly rough ride in the last three year. Unfortunately, they have held through a 69% decline in the share price in that time. And more recent buyers are having a tough time too, with a drop of 59% in the last year. And the share price decline continued over the last week, dropping some 9.0%. Importantly, this could be a market reaction to the recently released financial results. You can check out the latest numbers in our company report.
If the past week is anything to go by, investor sentiment for Cardiovascular Systems isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
Check out our latest analysis for Cardiovascular Systems
Cardiovascular Systems isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
Over the last three years, Cardiovascular Systems' revenue dropped 1.4% per year. That's not what investors generally want to see. The share price decline of 19% compound, over three years, is understandable given the company doesn't have profits to boast of, and revenue is moving in the wrong direction. Having said that, if growth is coming in the future, now may be the low ebb for the company. We don't generally like to own companies that lose money and can't grow revenues. But any company is worth looking at when it makes a maiden profit.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
NasdaqGS:CSII Earnings and Revenue Growth August 20th 2022We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for Cardiovascular Systems in this interactive graph of future profit estimates.
A Different Perspective
While the broader market lost about 9.3% in the twelve months, Cardiovascular Systems shareholders did even worse, losing 59%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Cardiovascular Systems that you should be aware of.
Cardiovascular Systems is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
投資股票不可避免地意味着買入一些業績不佳的公司。但從長遠來看心血管系統公司納斯達克(Sequoia Capital:CSII)股東在過去三年經歷了特別艱難的時期。不幸的是,在那段時間裏,他們挺過了股價下跌69%的局面。最近的購房者也很艱難,去年下降了59%。過去一週,股價繼續下跌,跌幅約為9.0%。重要的是,這可能是市場對最近發佈的財報的反應。你可以查看我們公司報告中的最新數字。
如果以過去一週為標準,投資者對心血管系統的情緒並不樂觀,所以讓我們看看基本面和股價之間是否存在錯配。
查看我們對心血管系統的最新分析
心血管系統公司目前沒有盈利,因此大多數分析師都會關注收入增長,以瞭解基礎業務的增長速度。未盈利公司的股東通常預期營收增長強勁。正如你可以想象的那樣,快速的收入增長,如果保持下去,往往會帶來快速的利潤增長。
在過去的三年裏,心血管系統公司的收入每年下降1.4%。這並不是投資者通常希望看到的。考慮到該公司沒有值得吹噓的利潤,而且收入正朝着錯誤的方向發展,股價在三年內下跌19%是可以理解的。話雖如此,如果未來出現增長,現在可能是該公司的低谷。我們通常不喜歡擁有虧損、收入無法增長的公司。但任何一家公司在首次盈利時都是值得關注的。
下圖顯示了收益和收入隨時間的變化情況(如果您點擊該圖,您可以看到更多詳細信息)。
NasdaqGS:CSII收益和收入增長2022年8月20日我們喜歡的是,內部人士在過去12個月一直在買入股票。話雖如此,大多數人認為盈利和收入增長趨勢是更有意義的業務指南。您可以在這裏看到分析師對心血管系統的預測互動未來利潤預估圖表。
不同的視角
雖然大盤在過去12個月裏下跌了約9.3%,但心血管系統的股東表現更差,下跌了59%。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本面的發展。遺憾的是,去年的業績為糟糕的表現畫上了句號,股東們在五年內面臨着每年8%的總虧損。一般來説,股價長期疲軟可能是一個壞信號,儘管反向投資者可能會希望研究這隻股票,希望它能好轉。我發現,把股價作為衡量企業業績的長期指標是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。例如,我們已經確定心血管系統的1個警示標誌這一點你應該知道。
心血管系統並不是內部人士唯一買入的股票。對於那些想要找到贏得投資這免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。
請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧